Drug Trial Radar · NCT07600476
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Jul 3, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Kupando GmbHIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Conditions
- Cutaneous Melanoma
- Mucosal Melanoma
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Merkel Cell Carcinoma of Skin
- Basal Cell Carcinoma of Skin
Interventions
KUP-101ADrug
Intravenous infusion of KUP-101A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and related TEAEsTime frame: From enrollment until three months after last dose administration
- Proportion of patients with dose-limiting toxicities (DLTs)Time frame: From start of treatment until one week after last dose administration.
- Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test resultsTime frame: From enrollment until three months after last dose administration
- Incidence of abnormal clinical findings in 12-lead ECG parameters and vital signsTime frame: From enrollment until three months after last dose administration
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie
Munich, Bavaria, Germany · Recruiting
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany · Recruiting
Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Dermatologie und Allergologie
Marburg, Hesse, Germany · Recruiting
Fachklinik Hornheide
Münster, North Rhine-Westphalia, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.